Evaluation of the efficacy of subcutaneous immunotherapy with a polymerised allergen extract of Dermatophagoides pteronyssinus in patients with hypersensitivity to mites

PROBELTE PHARMA has taken part in the project entitled “EVALUATION OF THE EFFICACY OF SUBCUTANEOUSIMMUNOTHERAPY WITH A POLYMERISED ALLERGEN EXTRACT OF DERMATOPHAGOIDES PTERONYSSINUS INPATIENTS WITH HYPERSENSITIVITY TO MITES” funded by the Centre for Technological Development and Innovation (CDTI) and the Ministry of Science and Innovation.
Immunotherapy with specific allergen extracts, known as “allergy shots”, involves administering an “extract” of the allergen responsible for the disease, with the aim of inducing the tolerance required to suppress the allergic response. It is currently considered the only treatment capable of changing the natural course of the disease.

PROBELTE PHARMA has developed a safer allergen immunotherapy treatment based on a dust mite (Dermatophagoides pteronyssinus) allergen extract that has been modified through polymerisation with glutaraldehyde.

The MAIN objective of this research project was to evaluate the efficacy and safety of a polymerised extract of D. pteronyssinus administered over 12 months to treat rhinoconjunctivitis (with or without asthma) caused by hypersensitivity to these mites in adult patients.

The project, file number IDI20190614C, was funded by the SPANISH PUBLIC ENTITY, THE CENTRE FORTECHNOLOGICAL DEVELOPMENT AND INNOVATION (CDTI) through the “Individual R&D Projects” call for proposals within the Recovery, Transformation and Resilience Plan. The project started in March 2019 and ended in June 2023, with a budget of €1,239,315.00 and a grant for €278,845.88.